Actively Recruiting
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2021-07-20
1000
Participants Needed
1
Research Sites
400 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor
S
Second Affiliated Hospital of Wenzhou Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD). Albuminuria and estimated glomerular filtration rate (eGFR) are currently recognized clinical indicators for early diagnosis of DN, however, the sensitivity and specificity are unsatisfactory. The early identification and treatment of DKD are conducive to lowering the risk of kidney damage by as much as 50%. Therefore, it is particularly critical to find new biomarkers to reflect the potential DKD lesions in the clinical silent period earlier and more accurately. Therefore, this study intends to analyze the differentially expressed lipids in early DKD, T2DM and healthy adults by mass spectrometry, and verify the related results by larger samples, so as to screen out early markers of DKD and achieve the ultimate goal of clinical application.
CONDITIONS
Official Title
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Aged between 20 and 80 years
- Good compliance with follow-up data available for more than 5 years
You will not qualify if you...
- Diagnosed with type 1 or type 2 diabetes mellitus according to 1999 WHO criteria
- Kidney diseases caused by other primary or secondary reasons
- Any acute infections
- Life expectancy less than 5 years based on the researcher's judgment
- Drug users or drug abusers
- Active sexually transmitted diseases such as viral hepatitis, AIDS, syphilis, or active infectious diseases like tuberculosis
- Any condition judged by the researcher to affect enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the Second Affiliated Hospital Zhejiang University Schoolof Medicine
Hangzhou, China, 310009
Actively Recruiting
Research Team
Z
Zheng Chao, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here